Kenneth Y Tsai

List of Publications by Year
in descending order

87 papers	8,556 citations	147801 31 h-index	53230 85 g-index
90 all docs	90 docs citations	90 times ranked	14213 citing authors

#	Article	IF	Citations
1	Genomic Classification of Cutaneous Melanoma. Cell, 2015, 161, 1681-1696.	28.9	2,562
2	p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature, 2002, 416, 560-564.	27.8	775
3	Role for the p53 homologue p73 in E2F-1-induced apoptosis. Nature, 2000, 407, 645-648.	27.8	656
4	Mutational Landscape of Aggressive Cutaneous Squamous Cell Carcinoma. Clinical Cancer Research, 2014, 20, 6582-6592.	7.0	493
5	Mutation of E2f-1 Suppresses Apoptosis and Inappropriate S Phase Entry and Extends Survival of Rb-Deficient Mouse Embryos. Molecular Cell, 1998, 2, 293-304.	9.7	361
6	An intact HDM2 RING-finger domain is required for nuclear exclusion of p53. Nature Cell Biology, 2000, 2, 563-568.	10.3	312
7	Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. Cell Reports, 2018, 23, 194-212.e6.	6.4	245
8	Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncology, The, 2014, 15, 1311-1318.	10.7	239
9	TAp63 Prevents Premature Aging by Promoting Adult Stem Cell Maintenance. Cell Stem Cell, 2009, 5, 64-75.	11.1	228
10	Analysis of Cell Mechanics in Single Vinculin-Deficient Cells Using a Magnetic Tweezer. Biochemical and Biophysical Research Communications, 2000, 277, 93-99.	2.1	194
11	Roles of the immune system in skin cancer. British Journal of Dermatology, 2011, 165, 953-965.	1.5	151
12	The RAC1 P29S Hotspot Mutation in Melanoma Confers Resistance to Pharmacological Inhibition of RAF. Cancer Research, 2014, 74, 4845-4852.	0.9	148
13	Comparative Electrotonic Analysis of Three Classes of Rat Hippocampal Neurons. Journal of Neurophysiology, 1997, 78, 703-720.	1.8	127
14	Cross-species identification of genomic drivers of squamous cell carcinoma development across preneoplastic intermediates. Nature Communications, 2016, 7, 12601.	12.8	123
15	The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy. Clinical Cancer Research, 2019, 25, 5961-5971.	7.0	118
16	IAPP-driven metabolic reprogramming induces regression of p53-deficient tumours in vivo. Nature, 2015, 517, 626-630.	27.8	117
17	TAp63 Is a Master Transcriptional Regulator of Lipid and Glucose Metabolism. Cell Metabolism, 2012, 16, 511-525.	16.2	96
18	APOBEC mutation drives early-onset squamous cell carcinomas in recessive dystrophic epidermolysis bullosa. Science Translational Medicine, 2018, 10, .	12.4	91

#	ARTICLE	IF	CITATIONS
19	Molecular cancer prevention: Current status and future directions. Ca-A Cancer Journal for Clinicians, 2015, 65, 345-383.	329.8	83
20	Systematic Epigenomic Analysis Reveals Chromatin States Associated with Melanoma Progression. Cell Reports, 2017, 19, 875-889.	6.4	78
21	ARF Is Not Required for Apoptosis in Rb Mutant Mouse Embryos. Current Biology, 2002, 12, 159-163.	3.9	70
22	Expression of cyclins E1 and E2 during mouse development and in neoplasia. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 13138-13143.	7.1	69
23	The genetics of skin cancer. American Journal of Medical Genetics Part A, 2004, 131C, 82-92.	2.4	68
24	BRAF inhibitors suppress apoptosis through off-target inhibition of JNK signaling. ELife, 2013, 2, e00969.	6.0	67
25	Diagnostic opportunities based on skin biomarkers. European Journal of Pharmaceutical Sciences, 2013, 50, 546-556.	4.0	64
26	Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions. International Journal of Dermatology, 2014, 53, 376-384.	1.0	62
27	Induced multipotency in adult keratinocytes through down-regulation of <i>Î"Np63</i> or <i>DGCR8</i>. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E572-81.	7.1	61
28	Lues Maligna in Early HIV Infection Case Report and Review of the Literature. Sexually Transmitted Diseases, 2009, 36, 512-514.	1.7	58
29	Collagenous vasculopathy: a report of three cases. Journal of Cutaneous Pathology, 2008, 35, 967-970.	1.3	51
30	Comparative profiles of BRAF inhibitors: the paradox index as a predictor of clinical toxicity. Oncotarget, 2016, 7, 30453-30460.	1.8	48
31	ARF mutation accelerates pituitary tumor development in Rb+/- mice. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 16865-16870.	7.1	42
32	miRNAâ€•and cytokineâ€‑associated extracellular vesicles mediate squamous cell carcinomas. Journal of Extracellular Vesicles, 2020, 9, 1790159.	12.2	34
33	Complement component C3 mediates Th1/Th17 polarization in human T-cell activation and cutaneous GVHD. Bone Marrow Transplantation, 2014, 49, 972-976.	2.4	33
34	Î"Np63/DGCR8-Dependent MicroRNAs Mediate Therapeutic Efficacy of HDAC Inhibitors in Cancer. Cancer Cell, 2016, 29, 874-888.	16.8	32
35	MELPREDICT: a logistic regression model to estimate CDKN2A carrier probability. Journal of Medical Genetics, 2006, 43, 501-506.	3.2	29
36	Sweet syndrome following vemurafenib therapy for recurrent cholangiocarcinoma. Journal of Cutaneous Pathology, 2014, 41, 326-328.	1.3	28

#	Article	IF	Citations
37	Sorafenib Suppresses JNK-Dependent Apoptosis through Inhibition of ZAK. Molecular Cancer Therapeutics, 2014, 13, 221-229.	4.1	27
38	Targeting ERK beyond the boundaries of the kinase active site in melanoma. Molecular Carcinogenesis, 2019, 58, 1551-1570.	2.7	26
39	Remote Assessment of Acne: The Use of Acne Grading Tools to Evaluate Digital Skin Images. Telemedicine Journal and E-Health, 2009, 15, 426-430.	2.8	25
40	Efficient mapping from neuroanatomical to electrotonic space. Network: Computation in Neural Systems, 1994, 5, 21-46.	3.6	23
41	Distinct TP63 Isoform-Driven Transcriptional Signatures Predict Tumor Progression and Clinical Outcomes. Cancer Research, 2018, 78, 451-462.	0.9	22
42	TCF7L1 promotes skin tumorigenesis independently of Î²-catenin through induction of LCN2. ELife, 2017, 6, .	6.0	20
43	Nodular presentation of secondary syphilis. Journal of the American Academy of Dermatology, 2007, 57, S57-S58.	1.2	19
44	BRAF inhibitor therapyâ€"associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression. Human Pathology, 2016, 50, 79-89.	2.0	18
45	Genomic and Single-Cell Landscape Reveals Novel Drivers and Therapeutic Vulnerabilities of Transformed Cutaneous T-cell Lymphoma. Cancer Discovery, 2022, 12, 1294-1313.	9.4	18
46	Histological Features Associated With Vemurafenib-Induced Skin Toxicities. American Journal of Dermatopathology, 2014, 36, 557-561.	0.6	17
47	Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors. Clinical Cancer Research, 2015, 21, 5215-5221.	7.0	17
48	Modulating multi-functional ERK complexes by covalent targeting of a recruitment site in vivo. Nature Communications, 2019, 10, 5232.	12.8	17
49	Distinct downstream targets manifest p53-dependent pathologies in mice. Oncogene, 2016, 35, 5713-5721.	5.9	16
50	TAp63-Regulated miRNAs Suppress Cutaneous Squamous Cell Carcinoma through Inhibition of a Network of Cell-Cycle Genes. Cancer Research, 2020, 80, 2484-2497.	0.9	16
51	A MAPK/miR-29 Axis Suppresses Melanoma by Targeting MAFG and MYBL2. Cancers, 2021, 13, 1408.	3.7	16
52	Skin Microbiome Variation with CancerÂProgression in Human Cutaneous Squamous Cell Carcinoma. Journal of Investigative Dermatology, 2022, 142, 2773-2782.e16.	0.7	16
53	Hyaluronic acid conjugates for topical treatment of skin cancer lesions. Science Advances, 2021, 7, .	10.3	15
54	Quantification of a Pharmacodynamic ERK End Point in Melanoma Cell Lysates: Toward Personalized Precision Medicine. ACS Medicinal Chemistry Letters, 2015, 6, 47-52.	2.8	14

#	ARTICLE	IF	CITATIONS
55	Systemic Adjuvant Therapy for Patients With High-Risk Melanoma. Archives of Dermatology, 2007, 143, 779-82.	1.4	12
56	MEK Is a Therapeutic and Chemopreventative Target in Squamous Cell Carcinoma. Journal of Investigative Dermatology, 2016, 136, 1920-1924.	0.7	12
57	JNK2 Is Required for the Tumorigenic Properties of Melanoma Cells. ACS Chemical Biology, 2019, 14, 1426-1435.	3.4	12
58	Pan-cancer analysis reveals TAp63-regulated oncogenic lncRNAs that promote cancer progression through AKT activation. Nature Communications, 2020, 11, 5156.	12.8	12
59	spatialGE: quantification and visualization of the tumor microenvironment heterogeneity using spatial transcriptomics. Bioinformatics, 2022, 38, 2645-2647.	4.1	12
60	Randomized controlled trial of fractionated laser resurfacing on aged skin as prophylaxis against actinic neoplasia. Journal of Clinical Investigation, 2021, 131, .	8.2	11
61	Hebbian learning is jointly controlled by electrotonic and input structure. Network: Computation in Neural Systems, 1994, 5, 1-19.	3.6	10
62	Primer on the human genome. Journal of the American Academy of Dermatology, 2007, 56, 719-735.	1.2	10
63	An analysis of the use of targeted therapies in patients with advanced Merkel cell carcinoma and an evaluation of genomic correlates of response. Cancer Medicine, 2021, 10, 5889-5896.	2.8	10
64	Kaposi sarcoma presenting as a cutaneous horn. Journal of the American Academy of Dermatology, 2011, 64, 447-448.	1.2	8
65	Differential Hairless Mouse Strain-Specific Susceptibility to Skin Cancer and Sunburn. Journal of Investigative Dermatology, 2019, 139, 1837-1840.e3.	0.7	8
66	Efficient mapping from neuroanatomical to electrotonic space. Network: Computation in Neural Systems, 1994, 5, 21-46.	3.6	7
67	Differential T‑cell subset representation in cutaneous squamous cell carcinoma arising in immunosuppressed versus immunocompetent individuals. Experimental Dermatology, 2016, 25, 245-247.	2.9	6
68	Noninvasive Assessment of Epidermal Genomic Markers of UV Exposure in Skin. Journal of Investigative Dermatology, 2021, 141, 124-131.e2.	0.7	6
69	Hebbian learning is jointly controlled by electrotonic and input structure. Network: Computation in Neural Systems, 1994, 5, 1-19.	3.6	6
70	Tumor Expression Quantitative Trait Methylation Screening Reveals Distinct CpG Panels for Deconvolving Cancer Immune Signatures. Cancer Research, 2022, 82, 1724-1735.	0.9	6
71	Evidence-Based Medicine. Archives of Dermatology, 2005, 141, 773-4.	1.4	5
72	A reagent to facilitate protein recovery from cells and tissues. Drug Delivery and Translational Research, 2012, 2, 297-304.	5.8	5

#	Article	IF	Citations
73	Optimized lysis buffer reagents for solubilization and preservation of proteins from cells and tissues. Drug Delivery and Translational Research, 2013, 3, 428-436.	5.8	5
74	Molecular and immune targets for Merkel cell carcinoma therapy and prevention. Molecular Carcinogenesis, 2019, 58, 1602-1611.	2.7	5
75	CERKL is upregulated in cutaneous squamous cell carcinoma and maintains cellular sphingolipids and resistance to oxidative stress*. British Journal of Dermatology, 2021, 185, 147-152.	1.5	5
76	Drug safety evaluation of vemurafenib in the treatment of melanoma. Expert Opinion on Drug Safety, 2013, 12, 767-775.	2.4	4
77	Integrative transcriptomic analysis for linking acute stress responses to squamous cell carcinoma development. Scientific Reports, 2020, 10, 17209.	3.3	4
78	The Origins of Merkel Cell Carcinoma: Defining Paths to the Neuroendocrine Phenotype. Journal of Investigative Dermatology, 2022, 142, 507-509.	0.7	4
79	miR-181a Promotes Multiple Protumorigenic Functions by Targeting TGFÎ²R3. Journal of Investigative Dermatology, 2022, 142, 1956-1965.e2.	0.7	4
80	When â€œEffectiveâ€•Prevention Agents Fail to Elicit Anticipated Effects: Challenges in Trial Design. Cancer Prevention Research, 2016, 9, 125-127.	1.5	3
81	Transposon mutagenesis identifies cooperating genetic drivers during keratinocyte transformation and cutaneous squamous cell carcinoma progression. PLoS Genetics, 2021, 17, e1009094.	3.5	2
82	Dynamic Gene Expression Analysis Links Melanocyte Growth Arrest with Nevogenesis. Cancer Research, 2009, 69, 9029-9037.	0.9	1
83	Assessing the Treatment of Nonmelanoma Skin Cancers. Archives of Dermatology, 2011, 147, 605.	1.4	1
84	CERKL is Upregulated in Cutaneous Squamous Cell Carcinoma and Maintains Cellular Sphingolipids and Resistance to Oxidative Stress. British Journal of Dermatology, 2020, , .	1.5	1
85	CERKL is Upregulated in Cutaneous Squamous Cell Carcinoma and Maintains Cellular Sphingolipids and Resistance to Oxidative Stress. British Journal of Dermatology, 2020, , .	1.5	1
86	Cover Image, Volume 58, Issue 9. Molecular Carcinogenesis, 2019, 58, i.	2.7	0
87	Introduction to Precision Medicine. Seminars in Cutaneous Medicine and Surgery, 2014, 33, 59-59.	1.6	0